Skip to content
Clinical Trials – home

Rokotetutkimuskeskus Finvac Oy

Research site

Finland Vuorikatu 18 B 3 Krs, 00100 Helsinki, Finland

  • 2 trials recruiting
  • Respiratory syncytial virus infection · Influenza · Influenza immunisation
  • Adults and children

About Specializations

Rokotetutkimuskeskus Finvac Oy in Helsinki, Finland specialises in clinical trials of conditions such as Respiratory syncytial virus infection, Influenza, Influenza immunisation, Meningococcal immunisation, and other specialisations. This site conducts important research.

Main research areas of the site

Bacterial Infections and Mycoses

At Rokotetutkimuskeskus Finvac Oy in Helsinki, research in Bacterial Infections and Mycoses focuses on pneumococcal infections and related preventive care. The trials are designed to assess the safety and immune response of vaccine candidates while helping to improve protection against serious bacterial disease in young children.

  • Studying pneumococcal infections and vaccine-based prevention
  • Evaluating the safety and tolerability of new pneumococcal vaccine candidates
  • Assessing how well these approaches support infection prevention in children

This work contributes to better vaccine development for common childhood bacterial illnesses and supports efforts to reduce the burden of preventable infection.

Respiratory Tract Diseases

The clinic is also active in Respiratory Tract Diseases research, with a strong emphasis on RSV prevention in infants and young children. These studies aim to determine whether candidate therapies can lower the risk of medically attended lower respiratory illness and improve protection during early life.

  • Focused on respiratory syncytial virus prevention in healthy infants
  • Testing whether a new approach can reduce RSV-associated lower respiratory infections
  • Supporting evaluation of respiratory infection prevention strategies

By examining both effectiveness and safety, the research helps advance better options for preventing serious respiratory illness in vulnerable pediatric populations.

Immune System Processes

Research in Immune system processes at this site centers on how vaccine candidates stimulate protective responses in the body. The studies are intended to better understand immunogenicity and safety, helping researchers determine whether new preventive tools can generate the desired immune protection.

  • Examining immune responses to vaccine candidates in young children
  • Tracking the safety profile of preventive therapies
  • Informing development of stronger immune-based protection against infection

These investigations support the broader goal of improving vaccination strategies through clearer understanding of how the immune system responds in early childhood.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Vuorikatu 18 B 3 Krs00100 HelsinkiFinland
Recruiting now
2 trials
Conditions studied
15

More sites in HelsinkiFinland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

19 clinical trials

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:GlaxoSmithKline Biologicals

COVID-19

Recruiting

Study of ibuzatrelvir tablets in non-hospitalized adults and adolescents with COVID-19 who are at high risk of developing severe illness

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ibuzatrelvir
  • Sponsor:Pfizer Inc.
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Sanofi Pasteur Inc.

Metapneumovirus infection

Not yet recruiting

Study on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:IVX-121
  • Sponsor:AstraZeneca AB

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Lyme disease

Not recruiting

Study on the Effectiveness and Safety of the VLA15 Vaccine for Preventing Lyme Disease in Healthy Individuals Aged 5 and Older

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:BORRELIA BURGDORFERI, SEROTYPE 1, OUTER SURFACE PROTEIN A FUSED VIA A LINKER TO BORRELIA BURGDORFERI, SEROTYPE 2, OUTER SURFACE PROTEIN A
  • Sponsor:Pfizer Inc.

Influenza

Not recruiting

Study on the Effectiveness of an MF59-Adjuvanted Influenza Vaccine Compared to a Non-Adjuvanted Vaccine in Adults Aged 65 and Older

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:65+ years · Healthy volunteers
  • Substances:A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)
  • Sponsor:Seqirus UK Limited

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Moderna Therapeutics Inc.

Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)
  • Sponsor:Abbott Biologicals B.V.

Study on the Effectiveness and Safety of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:534
  • Sponsor:Sanofi Pasteur Inc.

Study on the Safety and Immune Response of a Booster Dose of MenACYW Conjugate Vaccine in Children and Adolescents Previously Vaccinated for Meningococcal Infection

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Tetanus toxoid
  • Sponsor:Sanofi Winthrop Industrie
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.